Effect of tumor necrosis factor-alpha, interleukin-1 beta, and antibiotics on the killing of intracellular Staphylococcus aureus.
A bovine blood polymorphonuclear neutrophil system was used to determine the ability of cytokines, alone or in combination with various antibiotics, to enhance the intracellular killing of Staphylococcus aureus sequestered within these phagocytes. Pretreatment of blood polymorphonuclear neutrophils with human recombinant tumor necrosis factor-alpha, bovine macrophage supernatant tumor necrosis factor-alpha, or human recombinant interleukin-1 beta enhanced the killing of S. aureus by the phagocytes compared with that of untreated polymorphonuclear neutrophils. This enhancement was dose-dependent and required 30 min of contact between the cytokine and the blood polymorphonuclear neutrophils. However, mammary gland polymorphonuclear neutrophils, macrophages, and blood monocytes showed no enhanced killing activity following pretreatment with tumor necrosis factor. Pretreatment of polymorphonuclear neutrophils with tumor necrosis factor and subsequent exposure to various antibiotics after infection with S. aureus enhanced intracellular bacterial killing by certain antibiotics, including paldimycin, rifampin, and ciprofloxacin (antibiotics that normally kill intracellular S. aureus). However, no enhancement occurred with antibiotics that do not normally kill intracellular S. aureus. Cytokine therapy may be a useful adjunct to antibiotic therapy in the treatment of bovine staphylococcal infection and mastitis.
Sanchez
M S
MS
Upjohn Company, Kalamazoo, MI 49001.
Ford
C W
CW
Yancey
R J
RJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001770:Blood Bactericidal Activity; D002417:Cattle / Q000502:physiology*; D005260:Female; D007375:Interleukin-1 / Q000494:pharmacology*; D008264:Macrophages / Q000502:physiology; D008321:Mammary Glands, Animal / Q000166:cytology; D008414:Mastitis, Bovine / Q000188:drug therapy; D009000:Monocytes / Q000502:physiology; D009504:Neutrophils / Q000502:physiology; D010586:Phagocytes / Q000502:physiology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha